Drug Trial Radar · NCT01872702
Targeted Chemo-elimination (TCE) of Malaria
Last checked: Nov 20, 2026Latest source record: Aug 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,000
Actual
Start
Apr 2013
Primary completion
Jul 2017
Study completion Jul 2017
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mahidol Oxford Tropical Medicine Research Unit; National Centre for Parasitology, Entomology and Malaria Control, Cambodia; FHI 360; Oxford University Clinical Research Unit, Vietnam; National Malaria Control Program, Vietnam; Myanmar Oxford Clinical Research Unit; National Malaria Control Program, Myanmar; Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit; Shoklo Malaria Research Unit
- First posted
- Jun 7, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The overall aim of this study is two fold: 1. to pilot targeted chemo-elimination of plasmodium falciparum malaria in known areas of artemisinin resistance in South East Asia. 2. to understand the micro-epidemiology of malaria in these areas; chiefly, the prevalence and importance to on-going transmission of sub-clinical p.f malaria infections.
Conditions
- Plasmodium Falciparum Malaria
Interventions
malaria elimination using DP and low-dose primaquineDrug
Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
Primary outcomes
What the sponsor says the trial is designed to measure.
- prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine. (1017-13 and 23-15)Time frame: 12 months
- prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of targeted malaria elimination (1015-13)Time frame: 12 months
- prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 4 months after the first administration of target malaria-elimination (23-15)Time frame: 4 months
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Mahidol Oxford Clincal Research Unit, Myanmar
Rangoon, Burma
Pailin
Pailin, Cambodia
Savannakhet
Savannakhet, Laos
Shoklo Malaria Research Unit
Mae Sot, Changwat Tak, Thailand
Oxford University Clinical Research Unit - Vietnam
Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.